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In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, 
pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and 
Gram-negative pathogens from respiratory tract infections
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Department o f  Medical Microbiology, University Hospital St Radboud, University o f Nijmegen, 
Geert Grooteplein 24, Nijmegen, The Netherlands
Trovafloxacin, sparfloxacin, ciprofloxacin and levofloxacin were equally active against 
Moraxella catarrhalis, Haemophilus influenzae, Legionella pneumophila, Klebsiella pneumo­
niae, Enterobacter cloacae and Serratia marcescens. Ciprofloxacin was the most active 
compound against Pseudomonas aeruginosa (MlCd0 = 1 mg/L), followed by trovafloxacin 
(MICgo = 4 mg/L). Trovafloxacin was twice as active as sparfloxacin against Streptococcus 
pyogenes (MIC90 = 0.12 mg/L), Streptococcus pneumoniae (MICg0 = 0.12 mg/L) and Staphylo­
coccus aureus (MIC90 = 0.06 mg/L) (except quinoione-resistant, methicillin-resistant S. aureus, 
for which the MIC90 was 8 mg/L). Trovafloxacin was the most active compound against 
Enterococcus faecalis: 80% of strains were susceptible to 0.25 mg/L. There was complete 
cross-resistance between all fluoroquinolones.
Introduction
A  number of fluoroquinolones have recently been shown 
to be clinically effective for the treatment of community- 
and hospital-acquired respiratory tract infections.1,2 Most 
experience has been obtained with ciprofloxacin, ofloxacin 
and pefloxacin. Their activity against Gram-positive bac­
teria is limited, however. In the last five years several new 
quinolones with activity against Gram-positive bacteria 
have been evaluated in vitro, but improved activity against 
Gram-positive bacteria has often appeared to be associ­
ated with decreased activity against Gram-negative 
bacteria.3 Some drugs had high activity in vitro against 
Gram-positive and Gram-negative microorganisms4 but 
showed serious side effects in humans, requiring their 
withdrawal. In the present study the in-vitro activities of 
sparfloxacin and trovafloxacin were compared with those 
of older fluoroquinolones against Gram-positive and 
Gram-negative respiratory pathogens from community- 
acquired and hospital-acquired pneumonia.
Materials and methods*
A total of 498 clinical isolates from patients with respira­
tory tract infections, hospitalized in the University 
Hospital of Nijmegen, were studied.
MICs were determined in duplicate using a routine 
broth dilution method in microtitre plates.4 Media used 
were Isosensitest broth (Oxoid), supplemented with 2% 
lysed horse blood and Isovitalex (2.5%, BBL) for 
Haemophilus influenzae and buffered starch yeast extract 
broth for Legionella pneumophila.
Antimicrobial stock solutions were prepared by 
dissolving powdered ciprofloxacin, levofloxacin, ofloxacin 
and trovafloxacin in water, and powdered lomefloxacin, 
pefloxacin and sparfloxacin in 0.1 M NaOH. Ciprofloxacin 
was provided by Bayer AG (Leverkusen, Germany), 
levofloxacin and ofloxacin by Hoechst Pharma (Amster­
dam, The Netherlands), pefloxacin and sparfloxacin by 
Rh6ne-Poulenc Rorer (Amstelveen, The Netherlands), 
lomefloxacin by Searle Nederland (Maarssen, The 
Netherlands) and trovafloxacin by Pfizer (Capelle, The 
Netherlands).
The microtitre plates were filled with 100 \xL of double­
strength antibiotic test solution in each well. The inocula 
were prepared by taking four colonies of overnight 
cultures grown on appropriate media, which were added to
3 mL of sterile 0.85% NaCl to a McFarland turbidity 
standard of 0.5 (1.5 x  10s cfu/mL) and further diluted in 
10 mL of double-concentrated test broth to a final organ­
ism concentration of 3 X 106-5 X 106 cfu/mL. Each well 
was inoculated with 100 |xL of this suspension (final inocu-
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lum size 1.5 X 106-2.5 X 106 cfu/mL). The inoculum size 
and purity were controlled by plating 1 jxL of the bacterial 
suspension on appropriate media. The plates were incu­
bated at 37°C and growth was assessed after 24 and 48 h of 
incubation.
The MIC was defined as the lowest concentration pre­
venting visible growth in the test medium. Control strains 
used were Escherichia coli ATCC 25922, Pseudomonas 
aeruginosa ATCC 27853, Staphylococcus aureus ATCC 
29213 and Enterococcus faecalis ATCC 29212.
Results
The comparative activities of the strains are given in the 
Table.
Gram-negative organisms
Against Enterobacteriaceae, H, influenzae, Moraxella 
catarrhalis and L. pneumophila, ciprofloxacin, sparfloxacin 
and trovafloxacin were more active than levofloxacin, 
ofloxacin, lomefloxacin and pefioxacin. Ciprofloxacin, 
sparfloxacin and trovafloxacin were about twice as active 
as ofloxacin and lomefloxacin and at least eight times as 
active as pefioxacin. Levofloxacin was as active as cipro­
floxacin against Serratia marcescens, H. influenzae and 
M. catarrhalis, but showed less activity against the other 
Gram-negative organisms tested. Ciprofloxacin was the 
most active compound against P. aeruginosa, being twice 
as active as trovafloxacin, levofloxacin and sparfloxacin 
and four times as active as ofloxacin and lomefloxacin. 
Taking 2 mg/L as the breakpoint for susceptibility, the
activities of trovafloxacin, sparfloxacin, ciprofloxacin and 
levofloxacin towards Klebsiella pneumoniae, Enterobacter 
cloacae, S. marcescens, H. influenzae, M. catarrhalis and 
L. pneumophila were similar.
Gram-positive organisms
Trovafloxacin was twice as active as sparfloxacin against 
Streptococcus pyogenes, S. pneumoniae, E. faecalis and 
S. aureus. Seven of the MRSA strains and all the 
methicillin-susceptible strains were equally susceptible 
to trovafloxacin and sparfloxacin, with MIC90s of 0.06-0.12 
mg/L, but the three methicillin- and quinolone-resistant 
S. aureus (MQRSA) strains were inhibited only by 4 mg/L, 
8 mg/L and 16 mg/L trovafloxacin and 8 mg/L, 16 mg/L and 
32 mg/L sparfloxacin, respectively. These three strains 
were resistant to the other quinolones with MICs of 8-^32 
mg/L. Both penicillin-resistant and pencillin-susceptible 
£. pneumoniae strains were susceptible to trovafloxacin 
and sparfloxacin, but they were less susceptible to the 
other quinolones, Trovafloxacin was the most active 
quinolone against E. faecalis.
Discussion
Trovafloxacin and sparfloxacin showed high activity 
against Gram-positive bacteria without loss of Gram- 
negative spectrum. The most important feature of their 
antimicrobial spectrum was their activity against pneumo­
cocci irrespective of penicillin-susceptibility, with 90% of 
the strains susceptible to 0.12 mg/L of trovafloxacin and
0.25 mg/L of sparfloxacin. This has also been found by
Table. Antibacterial activities of seven fluoroquinolones against 498 respiratory pathogens (agents are
shown in descending order of activity)
Bacterium (n)
Haemophilus influenzae (50)
Moraxella catarrhalis (50)
MIC (mg/L) % Susceptible
Drug MIG«, range to « 2
sparfloxacin 0.015 0.015-0.03 100
ciprofloxacin 0.03 0.015-0.03 100
trovafloxacin 0.03 0.015-0.03 100
levofloxacin 0.03 0.015-0.06 100
ofloxacin 0.06 0.015-0.06 100
lomefloxacin 0.12 0.03-0.12 100
pefioxacin 0.5 0.12-1 100
sparfloxacin 0.03 0.015-0.03 100
trovafloxacin 0.03 0.015-0.03 100
ciprofloxacin 0.12 0.03-0.12 100
levofloxacin 0.12 0.03-0.12 100
ofloxacin 0.12 0.06-0.25 100
lomefloxacin 0.25 0.12-0.5 100
pefioxacin 1 0.12-1 100
mg/L
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Table. Continued
Bacterium (n) Drug
MIC (mg/L) 
MIC90 range
% Susceptible 
to =s2 mg/L
Legionella pneumophila (50) Sparfloxacin 0.015 0.015-0.03 1 0 0
trovafloxacin 0.015 0.015 1 0 0
ciprofloxacin 0.03 0.015-0.06 1 0 0
levofloxacin 0.03 0.015-0.03 1 0 0
ofloxacin 0.03 0.03-0.06 1 0 0
lomefloxacin 0.06 0.06-0.12 1 0 0
pefloxacin 0.5 0.25—0.5 1 0 0
Streptococcus pneumoniae trovafloxacin 0 . 1 2 0.06-0.25 1 0 0
( 1 0  penicillin resistant, sparfloxacin 0.25 0.12-0.5 1 0 0
39 penicillin susceptible) ciprofloxacin 2 0.5-2 1 0 0
levofloxacin 1 0.5-2 1 0 0
ofloxacin 2 1-4 96
lomefloxacin 8 4->32 0
pefloxacin 5*32 16->32 0
Streptococcus pyogenes (20) trovafloxacin 0 . 1 2 0.03-0.5 1 0 0
sparfloxacin 0.25 0.12-0.5 1 0 0
ciprofloxacin 0.5 0 .1 2 - 2 1 0 0
levofloxacin 1 0.25-2 1 0 0
ofloxacin 1 0.5-4 95
lomefloxacin 8 2-16 1 0
pefloxacin 5=32 8->32 0
Enterococcus faecalis (47) trovafloxacin 16 0.12-16 81
sparfloxacin >32 0.25->32 81
ciprofloxacin >32 0.25->32 79
levofloxacin >32 0.5->32 81
ofloxacin >32 l->32 55
lomefloxacin >32 2->32 2
pefloxacin >32 2->32 0
Staphylococcus aureus MSSA (20) trovafloxacin 0.06 0.015-0.06 100
sparfloxacin 0.12 0.03-0.5 100
ciprofloxacin 1 0.25-1 100
levofloxacin 0.5 0 .1 2 - 1 1 0 0
ofloxacin 1 0.25-4 95
lomefloxacin 2 0.5-16 90
pefloxacin 2 0.5-16 90
S. aureus MRSA (10) trovafloxacin 8 0.015-16 70
sparfloxacin 16 0.03->32 70
levofloxacin 16 0.25->32 70
ofloxacin >32 0.25->32 70
ciprofloxacin >32 0.25->32 70
lomefloxacin >32 0.5->32 60
pefloxacin >32 l->32 50
Klebsiella pneumoniae (50) sparfloxacin 1 0.015->32 90
ciprofloxacin 2 0.015->32 90
trovafloxacin 2 0.015->32 92
levofloxacin 2 0,015->32 90
ofloxacin 4 0.03->32 86
lomefloxacin 8 0.06->32 82
pefloxacin 4 0.12->32 88
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Bacterium (n) Drug
MIC (mg/L) 
MIC90 range
% Susceptible 
to «2 mg/L
Serratia marcescens (51) ciprofloxacin 4 0.015-8 8 6
Sparfloxacin 4 0.015-16 82
trovafloxacin 4 0.03-16 82
levofloxacin 4 0.03-8 84
ofloxacin 8 0.06-16 80
lomefloxacin 8 0.06-2*32 73
pefloxacin s*32 0.12-2=32 39
Enterobacter cloacae (50) ciprofloxacin 1 0.015-5*32 98
Sparfloxacin 1 0.015-3=32 98
trovafloxacin 1 0.015-16 90
levofloxacin 2 0.03-5=32 90
ofloxacin 4 0.03-5=32 8 8
lomefloxacin 8 0.06-^32 78
pefloxacin 8 0.25-3=32 76
Pseudomonas aeruginosa (51) ciprofloxacin 1 0.03-^32 90
trovafloxacin 4 0.12-5=32 8 6
levofloxacin 8 0.12-5*32 78
ofloxacin 16 0.12-5*32 78
sparfloxacin 8 0.12-^32 78
lomefloxacin 16 0.5-5a32 64
pefloxacin 5*32 1-3=32 16
Control strains
E. coli ATCC 25922 ciprofloxacin 0.015-0.03
sparfloxacin 0.015
trovafloxacin 0.015
levofloxacin 0.03
ofloxacin 0.03-0.06
lomefloxacin 0.06—0.25
pefloxacin 0.25
P. aeruginosa ATCC 28753 ciprofloxacin 0.12-0.25
trovafloxacin 0.25-0.5
sparfloxacin 0.5-1
levofloxacin 0.5-1
ofloxacin 1
lomefloxacin 1 - 2
pefloxacin 8
S. aureus ATCC29213 trovafloxacin 0.015 -0.03
sparfloxacin 0.06
ciprofloxacin 0.25 -0.5
levofloxacin 0.25 -0.5
ofloxacin 0.5
pefloxacin 1
lomefloxacin 1
E. faecalis ATCC 29212 trovafloxacin 0.12-0.25
sparfloxacin 0.25-0.5
ciprofloxacin 0.5-1
levofloxacin 1
ofloxacin 2-4
pefloxacin 4
lomefloxacin 4
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others.5,6 Serum concentrations of trovafloxacin and spar- 
floxacin in humans of 5=2 mg/L after oral dosing of 300 mg7 
should therefore be expected to exceed the MIC foi all 
pneumococci. These quinolones may therefore be 
welcome drugs in countries where a substantial percentage 
of pneumococci have become resistant to penicillin. 
Trovafloxacin is in clinical trials and in Europe the use of 
sparfloxacin is currently limited to the treatment of 
community-acquired pneumonia following the incidence 
of phototoxicity after its launch in France.
Like others8 we found MRSA strains less susceptible 
and MQRSA strains not susceptible to all quinolones as a 
result of complete cross-resistance between the older and 
newer quinolones.
Enterococcal infections have become increasingly 
important. Most enterococci tested were isolated from our 
intensive care units where ciprofloxacin is often used, We 
observed a significant rise in MIC towards enterococci 
since its introduction. In 1986 100% of enterococci were 
susceptible to =sl mg/L, compared with 50% in 1996, with 
29% moderately susceptible and 21% not susceptible 
(MIC > 2 mg/L). Similar reports have come from others,9 
The strains susceptible to ciprofloxacin were also suscept­
ible to trovafloxacin and sparfloxacin with MICs two or 
four times lower; the strains insusceptible to ciprofloxacin 
were also insusceptible to the newer drugs, indicating 
cross-resistance.
A number of Gram-negative organisms may be respon­
sible for hospital-acquired pneumonia. Among them 
K . pneumoniae, Enterobacter sp., Serratia marcescens and 
P. aeruginosa predominate. Resistance of these species to 
quinolones has been reported.10 Although we used 
ciprofloxacin with restriction for treatment of hospital- 
acquired pneumonia, we have also observed a substantial 
rise in MIC (eight- to 30-fold with 10% resistance) towards 
these problem organisms during the last ten years. 
Trovafloxacin and sparfloxacin were no more active than 
ciprofloxacin towards these strains.
In conclusion, trovafloxacin and sparfloxacin were more 
active against Gram-positive respiratory pathogens than 
were the older fluoroquinolones; their activities against 
Gram-negative organisms, except P. aeruginosa, were 
similar to that of ciprofloxacin. The latter drug may remain 
the drug of choice for treatment of P. aeruginosa infec­
tions.
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